Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Calusa Bio LLC has a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This action is assigned to 1 distinct examiner, SHOMER, ISAAC, in 1 distinct art unit. The 1 pending office action represents the company's current focus in the Biotechnology & Pharmaceuticals sector.
SHOMER, ISAAC is the busiest examiner, managing 1 pending office action. Because there is only 1 distinct examiner, the entire pending workload is concentrated with this individual. This single pending office action represents the company's current active prosecution within the 1 distinct art unit.
Practitioners should note that the 1 distinct examiner handles the entire pending inventory, allowing for a consistent prosecution path. The presence of 1 distinct art unit indicates that the company's current intellectual property efforts are concentrated in a specific technical field. This 1 pending office action serves as the sole active matter for the company within the Biotechnology & Pharmaceuticals technology area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOMER, ISAAC | 1 | 63.1% | +30.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18388724 | PARTICLE COMPOSITIONS COMPRISING POLYSARCOSINE LIPID CONJUGATES | SHOMER, ISAAC | 75d |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18388724 | PARTICLE COMPOSITIONS COMPRISING POLYSARCOSINE LIPID CONJUGATES | SHOMER, ISAAC | 1612 | §103Other | Final Rejection | 75d | Pending | Nov 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCalusa Bio LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Isaac Shomer has the most, with 1 of Calusa Bio LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
